

Table 1. Mentions Clinical trials showing erythropoietic improvement during iron chelation therapy in patients with lower risk MDS (5)

Study	Risk IPSS	RBC response	Neutrophil response	Plateletesponse
List et al (13)	Low/Int-1	15% (n=173)	15% (n=52)	22% (n=77)
Gattermann et al (14)	Low/Int-1	21.5% (n=247)	22% (n=50)	13% (n=100)
Nolte et al (15)	Low/Int-1	11% (n=50)	NR	NR
Angelucci et al (16)	Low/Int-1	Transfusion independence in 15.5% (n=152)	NR	NR